Navigation Links
Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon

Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities and clinical trials, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. Government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

CONTACT: Jerry Parrott, Vice President, Corporate Communications,+1-301-315-2777, Kate de Santis, Director, Inv
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:5/4/2015)... 4, 2015 PharmaEngine, Inc. (TWO:4162) today ... (NASDAQ: MACK ) with its sublicensing partner, ... announced that Baxter has submitted a marketing authorization ... for MM-398 (irinotecan liposome injection), also known as ... pancreas who have been previously treated with gemcitabine-based ...
(Date:5/4/2015)...  Oncobiologics, Inc., a biotherapeutics company focused on ... completed the construction of its GMP commercial launch ... Cranbury, New Jersey . The ... to utilize multiple technologies that enable rapid deployment ... use of the latest single-use technologies, the facility ...
(Date:5/4/2015)... HeartWare International, Inc . (NASDAQ: HTWR ), a leading ... revolutionizing the treatment of advanced heart failure, today announced that ... present at the Bank of America Merrill Lynch 2015 Health ... Thursday, May 14, 2015, at 10:00 a.m. PT (1:00 p.m. ... at the conference will be available via a link on ...
Breaking Medicine Technology:PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2
... a dynamic, service-oriented healthcare technology company has announced an ... and Practice Management software products. This update will enable ... the requirements set forth by the Centers for Medicare ... (Logo: http://photos.prnewswire.com/prnh/20101115/NY01712LOGO ) Currently, SequelMed ...
... capital, a burdensome and uncertain regulatory environment and lack ... the biggest threats to the biomedical industry,s growth over ... surveyed by CHI-California Healthcare Institute, BayBio and PwC US. ... quarters (74 percent) of biomedical industry CEOs surveyed said ...
Cached Medicine Technology:SequelMed Announces ANSI 5010 Upgrade for Its Users 2Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 2Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 3Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 4Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 5
(Date:5/4/2015)... New findings released today from a ... show that people diagnosed with a brain tumor needed ... clinical trials, at the time of diagnosis, and had ... about their course of treatment. The release of these ... brain tumor volunteer network, the ABTA CommYOUnityâ„¢, dedicated to ...
(Date:5/4/2015)... 04, 2015 Sheltering Arms announced that ... Hale House. The Mother Hale Learning Center meets a ... Childhood Education. Sheltering Arms will begin operating the site ... served by the center. , Opened in 2006, the ... weeks to five years, many of whom come from ...
(Date:5/4/2015)... May 04, 2015 Elisabeth Rosenthal’s ... a stir and showed the healthcare fraternity as ... healthcare procedure, the downside of balance billing. In ... healthcare provider billing a patient for the difference ... reimburse and what the provider chooses to charge. ...
(Date:5/4/2015)... Pennsylvania (PRWEB) May 04, 2015 World ... and hand cycle ride in the last decade arrived ... riding 110 miles in two days from the Pentagon ... non-profit saw 581 registered disabled and able-bodied participants work ... of America recognizes and honors the commitment and sacrifices ...
(Date:5/4/2015)... May 04, 2015 Fast on the ... documentary Trace Amounts, and Allison Folmar, JD, join over ... held internationally. , On Sunday, May 24, the conference ... autism possible?" Are you interested in Ryan Hinds' recovery ... winning our war against autism was written by ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4
... , WEDNESDAY, May 30 (HealthDay News) -- ... pneumonia patients, researchers say. The new study included ... who were admitted to hospitals and private practices in ... Community-acquired pneumonia, one of the leading infectious diseases in ...
... , , , , , ... , AUDIO: Smoking researchers at ... Click here for more information. , ... , , , , , ...
... it is beneficial to have a loved one present ... by researchers at the Johns Hopkins Bloomberg School of ... older adults suffering from poor mental health. They examined ... or hinders physician visit processes and found that older ...
... that can rapidly screen cells for leukemia or HIV ... can produce three-dimensional focusing of a stream of cells, ... counting CD4 cells," said Tony Jun Huang, associate professor ... of the diagnoses are done using flow cytometry." ...
... Henry Ford Hospital dermatologists say skin transplant surgery is ... skin disease vitligo. In a first study of its ... up to six months after surgery and found that the ... skin color. In eight patients with localized vitiligo, the treated ...
... who are blind in one side of their visual ... side. After passively hearing sounds for an hour, their ... of their visual field improved significantly. Neural pathways that ... this effect. "We have embarked on a whole new ...
Cached Medicine News:Health News:Genes predict if medication can help you quit smoking 2Health News:Genes predict if medication can help you quit smoking 3Health News:Genes predict if medication can help you quit smoking 4Health News:Patient mental health overlooked by physician when a family member is present 2Health News:Biochip-based device for cell analysis 2Health News:Biochip-based device for cell analysis 3Health News:Skin transplant offers new hope for vitiligo patients 2Health News:Hear to see: New method for the treatment of visual field defects 2
Adult size. Clear plastic. Accommodates either eye. Packaged 12 per box. Available in either adult or pediatric size....
... Flow rate: 45 ... micron. For filtering fluids ... in table; bi-directional membrane ... kg/cm2 (75 psi) via ...
Straight, right side cutting, 1.5 mm x 4 mm bite, length of shaft 115 mm, overall length 6.3 inches....
20 mm. Plastic, methylmethacrylate. Supplied sterile....
Medicine Products: